Sponsored by AbbVie

Quick Inventory of Depressive Symptomatology (QIDS)

The QIDS is a brief, 16-item self-rated assessment tool used to evaluate the symptoms of depression present in a patient during the past week.
Description: The QIDS is a brief, 16-item self-rated assessment tool used to evaluate the symptoms of depression present in a patient during the past week.
Disease States: Bipolar disorder, Major depressive disorder
Validated Uses: Screening, Diagnosis, Treatment Monitoring & Evaluation, Symptom Severity
Populations: Adolescent, Adult, Geriatric
Administration Method: Self-report
Time to administer: 5–15 minutes
Commonly used in: Clinical Trials & Research, Clinical Practice
Detailed Description: The QIDS is a 16-item, multiple-choice questionnaire in which depressive symptoms are rated on a 0–3 scale according to severity.1,8 Items are derived from the 9 diagnostic criteria for major depressive disorder used in the Diagnostic and Statistical Manual of Mental Disorders-IV (DSM-IV), including sadness, loss of interest or pleasure, poor concentration or decision-making, self-outlook, suicidal ideation, lack of energy, sleep disturbance, appetite change, and psychomotor agitation.1 The total score ranges from 0–27 and is obtained by adding the scores for each of the 9 symptom domains.1,7
Note: Although the QIDS was initially developed based on DSM-IV criteria, the scale is also compatible with the DSM-5. The core criteria for MDD are consistent across these editions11.
Scale Validity: The QIDS demonstrated 79% sensitivity and 81% specificity in a validation study conducted in 596 adult outpatients with dysthymia living in the United States.1
Alternative Versions: The 16-item QIDS scale was derived from a longer, 30-item Inventory of Depressive Symptomatology (IDS), originally published in 1986 and updated in 1996.1,7 The more comprehensive IDS not only assesses the core diagnostic criteria for major depressive disorder listed in the DSM-IV, but also commonly associated symptoms (e.g., anxiety, irritability) and atypical features (e.g., leaden paralysis, interpersonal rejection sensitivity).1,7 Please note that the shortened QIDS is contained entirely within the IDS and thus can be extracted if the longer tool is administered.1 The 16-item QIDS is also available in a clinician-rated format.1 Items are identical across the two formats.7
Cited Limitations: No limitations have been identified in the literature.

Footnotes:

†Although the 16-item QIDS is described here, we include information about alternative versions for your general awareness and convenience. These alternative versions are sometimes used by different practitioners or in clinical trial or research settings.

Supporting references for the filters are as follows:
Disease States: Major depressive disorder (MDD)1,2, Bipolar disorder (BD)3,4; Validated Uses: Screening (MDD)2, Diagnosis (MDD)2, Treatment Monitoring & Evaluation (BD & MDD)1-4, Symptom Severity (BD & MDD)1,3,4; Populations: Adolescent5, Adult1,2, Geriatric6; Administration Method: Self-report1,7; Time to administer: 5–15 minutes8; Commonly used in: Clinical Trials & Research1,4,7,9, Clinical Practice1,3,7,10

References:

  1. Rush, AJ et al. Biological Psychiatry. 2003;54(5):573-583.
  2. Beidas, RS et al. Cogn Behav Pract. 2015;22(1):5-19.
  3. Bernstein, IH et al. Int J Methods Psychiatr Res. 2009;18(2):138-146.
  4. Tohen, M et al. Clinical trial design challenges in mood disorders.  (Elsevier Inc., 2015).
  5. Bernstein, IH et al. Int J Methods Psychiatr Res. 2010;19(4):185-194.
  6. Doraiswamy, PM et al. Acta Psychiatr Scand. 2010;122(3):226-234.
  7. About the IDS and QIDS. IDS/QIDS website. 2020. http://www.ids-qids.org/about.html. Accessed June 15, 2020.
  8. IDS-QIDS Administration. IDS/QIDS website. 2020. http://www.ids-qids.org/administration.html. Accessed June 15, 2020.
  9. Quiroz, JA et al. JAMA Psychiatry. 2016;73(7):675-684.
  10. Cerimele, JM et al. Psychiatr Serv. 2019;70(5):396-408.
  1. Center for Behavioral Health Statistics and Quality. 2014 National Survey on Drug Use and Health: DSM-5 Changes: Implications for Child Serious Emotional Disturbance (unpublished internal documentation). 2016. Substance Abuse and Mental Health Services Administration. Rockville, mD.

Welcome To NP Psych Navigator

This website is intended for healthcare professionals inside the United States.
Please confirm that you are a healthcare professional inside the US.

No, I am not US Healthcare professional

You are now leaving NP Psych Navigator

Links to sites outside of NP Psych Navigator are provided as a resource to the viewer. AbbVie Inc accepts no responsibility for the content of non-AbbVie linked sites.

Redirect to:

Please to bookmark content